Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (71-80 of 207) with videos related to

Pageof 21
Sort By:
Journal of Neuro-Oncology|November 20, 2008
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)Teri N Kreisl, Andrew B Lassman, Paul S Mischel, et al.
Cancer Research|June 28, 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutationHuisheng Wang, Sherif Daouti, Wen-Hui Li, et al.
Oncogene|May 14, 2003
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsRoberto Bianco, Incheol Shin, Christoph A Ritter, et al.
Cancer|December 11, 2014
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancerRona Yaeger, Elizabeth Cowell, Joanne F Chou, et al.
Molecular Imaging|March 16, 2012
Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imagingMikhail Doubrovin, Jian T Che, Inna Serganova, et al.
Plos One|August 30, 2007
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsLucia Regales, Marissa N Balak, Yixuan Gong, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Cancer Discovery|June 4, 2015
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerErin M Tricker, Chunxiao Xu, Sharmeen Uddin, et al.
Molecular Cell|January 16, 2007
An acetylation site in the middle domain of Hsp90 regulates chaperone functionBradley T Scroggins, Kenneth Robzyk, Dongxia Wang, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 22, 2005
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancerMichael J Morris, Carlos Cordon-Cardo, William K Kelly, et al.
Pageof 21

Showing results (71-80 of 207) with videos related to

Sort By:
Pageof 21
Journal of Neuro-Oncology|November 20, 2008
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)Teri N Kreisl, Andrew B Lassman, Paul S Mischel, et al.
Cancer Research|June 28, 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutationHuisheng Wang, Sherif Daouti, Wen-Hui Li, et al.
Oncogene|May 14, 2003
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsRoberto Bianco, Incheol Shin, Christoph A Ritter, et al.
Cancer|December 11, 2014
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancerRona Yaeger, Elizabeth Cowell, Joanne F Chou, et al.
Molecular Imaging|March 16, 2012
Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imagingMikhail Doubrovin, Jian T Che, Inna Serganova, et al.
Plos One|August 30, 2007
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsLucia Regales, Marissa N Balak, Yixuan Gong, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Cancer Discovery|June 4, 2015
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerErin M Tricker, Chunxiao Xu, Sharmeen Uddin, et al.
Molecular Cell|January 16, 2007
An acetylation site in the middle domain of Hsp90 regulates chaperone functionBradley T Scroggins, Kenneth Robzyk, Dongxia Wang, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 22, 2005
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancerMichael J Morris, Carlos Cordon-Cardo, William K Kelly, et al.
Pageof 21